The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of R-ICE (rituximab-ifosfamide-carboplatin-etoposide) with lenalidomide (R2-ICE) in patients with first-relapse/primary refractory diffuse large B-cell lymphoma (DLBCL) in academic and community cancer research united (ACCRU) network.
 
Francis Guerra-Bauman
No Relationships to Disclose
 
Betsy LaPlant
No Relationships to Disclose
 
William R. Macon
No Relationships to Disclose
 
Thomas E. Witzig
Consulting or Advisory Role - Abbvie/Genentech (Inst); Celgene (Inst); Cellectar; Epizyme; Immune Design; Incyte (Inst); Karyopharm Therapeutics; MorphoSys (Inst); Portola Pharmaceuticals; Seagen (Inst); Tessa Therapeutics
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Kura Oncology (Inst)
 
Umar Farooq
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Celgene (Inst); Genentech (Inst); MorphoSys (Inst)
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)
 
Tatyana Feldman
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb; Kite, a Gilead company; Pharmacyclics/Janssen; Seagen; Takeda
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Seagen
Speakers' Bureau - Abbvie; Celgene; Janssen; Kite, a Gilead company; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Cell Medica (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Pfizer (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Trillium Therapeutics (Inst); Viracta Therapeutics (Inst); Viracta Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Kite, a Gilead company; Pharmacyclics; Seagen; Takeda